BenevolentAI is a leading, clinical-stage AI-enabled drug discovery company. Through the combined capabilities of its AI platform, scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
BenevolentAI has a proven track-record of scientifically validated discoveries. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, spanning from target discovery to clinical studies, and it maintains successful commercial collaborations with leading pharmaceutical companies. BenevolentAI also identified Eli Lilly's baricitinib as a repurposing drug candidate for COVID-19, which has been authorised for emergency use by the FDA.
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Nick Keher, BenevolentAI’s CFO, is scheduled to present at 10.20 AM on Thursday 17th November at the upcoming Jefferies London Healthcare Conference.
Joanna Shields, CEO of BenevolentAI, will speak at the Apex EMEA Family Office Symposium in a panel moderated by Ben Thorpe of Goldman Sachs.
